These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Study suggests initiating saquinavir in early disease may increase duration of response. AIDS Patient Care STDS; 1997 Apr; 11(2):97-8. PubMed ID: 11361774 [No Abstract] [Full Text] [Related]
4. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection. Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P; Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388 [TBL] [Abstract][Full Text] [Related]
5. Saquinavir/low-dose ritonavir: its use in HIV infection. Johnson M; Peters B AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107 [TBL] [Abstract][Full Text] [Related]
6. [A further option in PI therapy. Approval of a new protease inhibitor in the USA]. MMW Fortschr Med; 2005 Apr; 147 Spec No 1():30. PubMed ID: 16385868 [No Abstract] [Full Text] [Related]
7. Fortovase approved: new saquinavir formulation. James JS AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907 [TBL] [Abstract][Full Text] [Related]
8. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763 [No Abstract] [Full Text] [Related]
10. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990 [TBL] [Abstract][Full Text] [Related]
11. Saquinavir switch study stopped. Treat Rev; 1997 Apr; (No 24):6. PubMed ID: 11364285 [TBL] [Abstract][Full Text] [Related]
12. Soft gel saquinavir has high exposure. AIDS Alert; 1997 Dec; 12(12):143-4. PubMed ID: 11364835 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up. Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062 [TBL] [Abstract][Full Text] [Related]
14. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
16. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Losso MH; Lourtau LD; Toibaro JJ; Saenz C; González C Antivir Ther; 2004 Dec; 9(6):1031-3. PubMed ID: 15651762 [No Abstract] [Full Text] [Related]
17. NDA submitted for new formulation of saquinavir. AIDS Patient Care STDS; 1997 Aug; 11(4):288-9. PubMed ID: 11361847 [No Abstract] [Full Text] [Related]